With the rapid development of biotechnology and the deepening of digital transformation, the pharmaceutical raw material industry is undergoing changes. The deep integration of these two trends not only brings innovation power and efficiency improvement to the industry, but also opens up a new development space and business model.

1. biotechnology innovation: opening a new era of customized drug raw materials

New advances in biotechnology, such as gene editing (CRISPR-Cas9), synthetic biology, cell culture technology, etc., are profoundly changing the production of pharmaceutical raw materials. These technologies make the production of pharmaceutical raw materials more environmentally friendly, and can be customized to meet the treatment needs of individual patients.

Gene editing technology: by modifying the gene sequence of microorganisms or cells, optimize their metabolic pathways, improve the yield and purity of target products, and reduce the generation of by-products.
Synthetic biology: the design and construction of entirely new biological systems for the production of specific pharmaceutical raw materials, such as the production of complex bioactive molecules by microbial fermentation.
Cell culture technology: culture cells to produce biopharmaceutical raw materials under the culture conditions of serum-free or without the components of the source of the plant, improving production efficiency and safety.

Deepening 2. Digital Transformation: Building an Ecosystem of Smart Pharmaceutical Ingredients

Digital transformation not only improves the production efficiency of the pharmaceutical raw material industry, but also realizes the transparency and intelligence of the supply chain through data analysis and intelligent decision-making.

Intelligent manufacturing: Use the Internet of Things, big data, artificial intelligence and other technologies to realize the automation, intelligence and real-time monitoring of the production process, and improve production efficiency and product quality.
Digitalization of the supply chain: through the digital platform, the seamless connection between suppliers, manufacturers, distributors and customers is realized, and the synergy efficiency and response speed of the supply chain are improved.
Data-driven R & D: The use of bioinformatics, machine learning and other technologies to mine and analyze large amounts of biological and chemical data to accelerate the development of new drugs and new pharmaceutical raw materials.
3. Fusion Innovation: Synergies between Biotechnology and Digital Transformation

The deep integration of biotechnology and digital transformation has brought innovation opportunities to the pharmaceutical raw material industry. This integration not only improves production efficiency and product quality, but also promotes the discovery and application of new pharmaceutical raw materials.

The combination of bioinformatics and AI: through bioinformatics analysis, the identification of potential drug targets, and then combined with AI algorithm for drug design, greatly shorten the new drug development cycle.
Intelligent bio-manufacturing: using artificial intelligence to optimize the bio-fermentation process to achieve the regulation and production of target products.
Personalized medical raw material customization: combined with the patient's genetic information and disease characteristics, the use of biotechnology to produce personalized drug raw materials.